HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

'It looks like this hypothesis will pan out': Cullinan unveils data building case for autoimmune TCEs

When it comes to turning T-cell therapies toward autoimmune diseases, CAR-Ts have been leading the way. But another red-hot modality is also beginning to show potential in the clinic.

By FierceBiotech · Jun 6, 2026 · via FierceBiotech
'It looks like this hypothesis will pan out': Cullinan unveils data building case for autoimmune TCEs

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Takeda takes $2.5B legal charge after pay-for-delay verdict, swings to loss for '25
The WeekFiercePharma ↗
Takeda takes $2.5B legal charge after pay-for-delay verdict, swings to loss for '25
The company adjusted its full-year 2025 earnings to account for a legal provision of 402.5 billion JPY ($2.5 b…
Jun 6, 2026
Medicare Advantage 2026: Low Premiums, High Limits, Tight Control
The WeekBriefing
Medicare Advantage 2026: Low Premiums, High Limits, Tight Control
Three-quarters of Medicare Advantage enrollees pay no added premium in 2026, but rising out-of-pocket caps and…
Jun 6, 2026
Opinion: I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action
The WeekSTAT News ↗
Opinion: I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action
"Ebola is an unforgiving enemy," writes Tom Frieden, who led the U.S. CDC response to the 2014-2016 Ebola outb…
Jun 6, 2026